Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

Summary

The investigational drug being tested in this study is palbociclib. Palbociclib is considered experimental because it is not approved by the FDA for the treatment of all cancers. Palbociclib is currently approved for use in breast cancer. Palbociclib is a drug belonging to a family of drugs called kinase inhibitors. These drugs slow or stop the activity of particular proteins involved in the growth of human cells and in the abnormal growth of cancer cells. Blocking these proteins may decrease or stop tumor growth. The purpose of this study is to assess the safety of the study drug, to see how well it is tolerated, and also to find a safe dose range of the study drug in patients with specific kinds of tumor genetic changes.

Timeline

Start

2018-07-01

Primary completion

2020-02-01

Completion

2024-02-01

Outcome

Outcome not reported

Stopped (Business): “No study funding available.”

Drugs

Indications